NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Stock Price, Quote & AI Analysis
Live NAMS stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for NewAmsterdam Pharma Company N.V. Ordinary Shares.
TradeVae provides AI-driven analysis and real-time market intelligence for NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
NewAmsterdam Pharma Company N.V. Ordinary Shares's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
NewAmsterdam Pharma Company N.V. Ordinary Shares Overview
Company information
Company Overview
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Company Details
Technical Indicators
Key technical analysis metrics and signals
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...